Skip to main content

Disbrow Joshua R.'s Form 4 filing

Aytu Biopharma, IncAYTU · filed Mar 3, 2025

Accession no.
0001437749-25-005873
Filed
Mar 3, 2025
Trade date
Feb 28, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction. Open-market purchases total $19.5K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Disbrow Joshua R.CIK 0001566240Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 28, 2025Common StockPPurchaseAcquired+15,000$1.30F1+$19,50086,591Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)